Filter posts

Watchdog Report Reaffirms Concerns With Fail First

A new report by the Office of Inspector General at the U.S. Department of Health …

As Out-of-Pocket Costs Rise, Insurers Spend Big on Administrative Costs

It seems every week the insurance industry is busy pointing the finger at biopharmaceutical innovators …

New Report Offers “Distorted View” of Biopharma Industry

This week, the Minority Staff of the U.S. Senate Committee on Finance released a report …

Defining and Communicating Value

BIO President and CEO Jim Greenwood has defined value-based agreements as an important part of …

Ending the Opioid Epidemic Through Innovation

Every day the opioid epidemic is destroying lives and communities across the country. Dr. Jeremy …

At #BIO2018, A Look at the State of Innovation

Innovation is at the forefront of the biotechnology industry, and at the 2018 BIO International Convention, …

Notable Limitations of the Latest Drug Pricing Report

In a new report, Sen. Claire McCaskill, the ranking Democratic lawmaker on the Senate Homeland …

#BIOCEO18: A Bright Future

“A transformative year in medicine.” That’s how BIO President and CEO Jim Greenwood recently described …

#BIOCEO18: “A Moment Decades in the Making”

It’s a first-of-its-kind gene therapy ever approved by the U.S. Food and Drug Administration, marking …

“A Transformative Year in Medicine”

2017 will be remembered as an exciting year for biopharmaceutical innovation. Not only did we …